Health Canada Grants Apricus Biosciences Pre-NDS Meeting for Femprox for Female Sexual Arousal Disorder - Yahoo Finance

Femprox(R) is a topically applied formulation of 0.4% alprostadil delivered using dodecyl 2-(N, N dimethylamino)-propionate hydrochloride (DDAIP HCl) or NexACT(R), Apricus Bio's proprietary drug delivery technology. To the Company's current ...

Apricus Biosciences Announces Poster Presentation of Femprox(R) Phase III Clinical Data at American Urological Association Annual Meeting - GlobeNewsWire (press release)

Femprox ® is an alprostadil-based cream intended for the treatment of FSAD. Apricus Bio has completed nine clinical studies to date, including one, 98-patient Phase II study in the U.S. and a 400-patient Phase III study in China. It is the Company's ...

Apricus Biosciences granted pre-NDS meeting for Femprox - Yahoo Finance

Apricus Biosciences announced that Health Canada has granted the Company's request for a Pre-New Drug Submission meeting to obtain regulatory guidance from the agency for Femprox, its topical alprostadil cream for the treatment of female sexual ...

Health Canada grants Apricus Pre-NDS meeting for Femprox to treat female sexual arousal disorder - pharmabiz.com

Health Canada has accepted the Apricus Biosciences Inc.'s request for a Pre-New Drug Submission (Pre-NDS) meeting to obtain regulatory guidance from the agency for Femprox, its topical alprostadil cream for the treatment of female sexual arousal disorder (FSAD).

Apricus Biosciences Announces Poster Presentation of Femprox Phase III Clinical Data at American Urological Association Annual Meeting - ad-hoc-news.de

About Femprox(r) Femprox(r) is an alprostadil-based cream intended for the treatment of FSAD. Apricus Bio has completed nine clinical studies to date, including one, 98-patient Phase II study in the U.S. and a 400-patient Phase III study in China.

China Nuokang Bio-Pharmaceutical Inc. to Report First Quarter 2012 Financial Results - GlobeNewsWire (press release)

Nuokang's principal products include Baquting®, China's leading hemocoagulase product by market share; Kaitong®, a lipid emulsion alprostadil product for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post ...

China Nuokang Bio-Pharmaceutical Inc. Announces Receipt of "Going Private" Proposal - msnbc.com

Nuokang's principal products include Baquting®, China's leading hemocoagulase product by market share; Kaitong®, a lipid emulsion alprostadil product for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders ...

Apricus Biosciences Announces First Quarter 2012 Financial Results Conference Call and Provides Corporate Update - NASDAQ

In addition, the Company is evaluating multiple opportunities to expand into one of the largest Alprostadil markets and one of the largest erectile dysfunction markets in Europe in anticipation of the potential approval of Vitaros® later this y ...

DGAP-News: Apricus Biosciences Announces First Quarter 2012 Financial Results Conference Call and Provides Corporate Update - finanztreff

In addition, the Company is evaluating multiple opportunities to expand into one of the largest Alprostadil markets and one of the largest erectile dysfunction markets in Europe in anticipation of the potential approval of Vitaros(r) later this year or early 2013.